| 摘要 |
FIELD: medicine. ^ SUBSTANCE: method involves introduction to a patient suffering a gastrointestinal stromal tumour (GIST) characterised by mutations chosen from a group KIT T670I, V454A and PDGFRA D842V of an effective amount of midostaurin. Use of the invention allows to treat the GIST with the mutations KIT T670I, V454A and PDGFRA D842V, causing imatinib resistance, due to inhibition of autophosphorylation of KIT kinase enabled by midostaurin action. ^ EFFECT: higher efficacy of the composition. ^ 7 cl, 1 tbl, 2 ex |
